Get the Stockscreener App
1.42
2.74%
-0.04
After Hours:
1.42
Medicinova Inc stock is traded at $1.42, with a volume of 32,170.
It is down -2.74% in the last 24 hours and down -6.58% over the past month.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
See More
Previous Close:
$1.46
Open:
$1.445
24h Volume:
32,170
Relative Volume:
0.40
Market Cap:
$69.89M
Revenue:
$409.70K
Net Income/Loss:
$-12.00M
P/E Ratio:
-5.8078
EPS:
-0.2445
Net Cash Flow:
$-9.81M
1W Performance:
+2.16%
1M Performance:
-6.58%
6M Performance:
+11.81%
1Y Performance:
-3.40%
1-Day Range:
$1.39
$1.47
1-Week Range:
$1.38
$1.5668
52-Week Range:
$1.13
$1.96
Medicinova Inc Stock (MNOV) Company Profile
Name
Medicinova Inc
Sector
Industry
Phone
858-373-1500
Address
4275 EXECUTIVE SQUARE, LA JOLLA, CA
Compare MNOV vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.42 | 71.86M | 409.70K | -12.00M | -9.81M | -0.2445 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Initiated | H.C. Wainwright | Buy |
| Mar-10-21 | Initiated | Maxim Group | Buy |
| Mar-25-19 | Resumed | B. Riley FBR | Buy |
| Mar-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-18-17 | Initiated | Credit Suisse | Outperform |
| Jan-04-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-24-12 | Downgrade | MLV & Co | Buy → Hold |
| Oct-18-11 | Reiterated | MLV Capital | Buy |
| Jun-22-11 | Initiated | Global Hunter Securities | Buy |
| May-12-10 | Initiated | Wedbush | Outperform |
| Nov-12-08 | Reiterated | Ladenburg Thalmann | Buy |
| May-15-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jul-09-07 | Initiated | Punk, Ziegel & Co | Buy |
View All
Medicinova Inc Stock (MNOV) Latest News
Medicinova Inc (NASDAQ:MNOV) Reiterates Buy Rating - FXDailyReport.Com
Maxim Group Maintains MediciNova(MNOV.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Maxim Group Reiterates "Buy" Rating for MediciNova (NASDAQ:MNOV) - MarketBeat
MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
MediciNova Inc stock draws attention amid biotech pipeline momentum and analyst upside calls - AD HOC NEWS
MediciNova (NASDAQ:MNOV) Upgraded at Zacks Research - Defense World
MediciNova (NASDAQ:MNOV) Raised to "Hold" at Zacks Research - MarketBeat
What is HC Wainwright’s Estimate for MediciNova Q1 Earnings? - Defense World
Q1 Earnings Estimate for MediciNova Issued By HC Wainwright - MarketBeat
HC Wainwright & Co. initiates coverage of MediciNova (MNOV) with buy recommendation - MSN
Stock Analysis: Can MediciNova Inc continue delivering strong returnsQuarterly Risk Review & Verified Swing Trading Watchlist - baoquankhu1.vn
MediciNova (NASDAQ:MNOV) Now Covered by HC Wainwright - MarketBeat
MediciNova to Participate at the 38th Annual ROTH Conference - Bitget
This Cohu Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
MediciNova Inc Stock (ISIN: US58468P2038) Surges on Clinical Trial Momentum—Analysts See 469% Upsi - AD HOC NEWS
MediciNova, Inc. 2025 Annual Report: Advancing MN-166 and MN-001 Therapies for Neurological and Metabolic Diseases - Minichart
MNOV Stock Price, Quote & Chart | MEDICINOVA INC (NASDAQ:MNOV) - ChartMill
Medicinova 2025 10-K: Revenue $0.41M, EPS $(0.24) - TradingView
MediciNova (NASDAQ: MNOV) highlights MN-166 and MN-001 progress in annual report - Stock Titan
Quarterly Recap: What is the next catalyst for MediciNova IncChart Signals & Fast Moving Trade Plans - baoquankhu1.vn
Trend Review: Is MediciNova Inc a stock for growth or value investorsWeekly Trading Summary & AI Forecasted Stock Moves - baoquankhu1.vn
MediciNova (NASDAQ:MNOV) Stock Passes Above 200-Day Moving AverageShould You Sell? - MarketBeat
Can MediciNova Inc continue delivering strong returnsMarket Activity Recap & Weekly Setup with ROI Potential - baoquankhu1.vn
Aug Analyst Calls: Can AACG be recession proofJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
MediciNova (MNOV) Price Target Increased by 11.11% to 10.20 - Nasdaq
Breakout Watch: What analysts say about MediciNova Inc stockGDP Growth & Daily Growth Stock Investment Tips - baoquankhu1.vn
Market Moves: Can MediciNova Inc continue delivering strong returns2025 Stock Rankings & Risk Managed Trade Strategies - baoquankhu1.vn
MediciNova: Q4 Earnings Snapshot - Stamford Advocate
MediciNova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
MediciNova (NASDAQ:MNOV) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
Aug PreEarnings: What analysts say about MediciNova Inc stockJuly 2025 Setups & Daily Profit Focused Stock Screening - baoquankhu1.vn
Can MediciNova Inc. continue delivering strong returnsJuly 2025 EndofMonth & Long-Term Safe Return Strategies - mfd.ru
MediciNova reports preliminary 2025 financial results in Tokyo filing By Investing.com - Investing.com India
MediciNova Financial Report: Q4 & Annual 2025 ResultsLoss & Revenue FiguresNews and Statistics - IndexBox
MediciNova reports preliminary 2025 financial results in Tokyo filing - Investing.com
4875.T MediciNova (JPX) JPY 254.00 pre-earnings 19 Feb: catalysts to watch - Meyka
MediciNova, Inc. (NASDAQ:MNOV) Short Interest Update - MarketBeat
MediciNova (MNOV) Projected to Post Earnings on Wednesday - MarketBeat
Does MediciNova Inc. have strong fundamentalsRisk Management & Fast Exit and Entry Trade Guides - mfd.ru
MNOV Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
MediciNova (NASDAQ:MNOV) Shares Pass Above 200-Day Moving AverageHere's What Happened - MarketBeat
MediciNova (NASDAQ:MNOV) Shares Pass Above 200-Day Moving Average – Here’s What Happened - Defense World
RSI Check: Is MediciNova Inc a stock for growth or value investorsQuarterly Portfolio Summary & Weekly Top Performers Watchlists - baoquankhu1.vn
Performance Recap: Is MediciNova Inc backed by strong institutional buyingLong Setup & Daily Profit Maximizing Tips - baoquankhu1.vn
MediciNova (MNOV) Price Target Increased by 28.57% to 9.18 - Nasdaq
Drug Developer Uncovers Excellent Progress in 200-Patient ALS Study - streetwisereports.com
Trading Action: Is MediciNova Inc. a stock for growth or value investorsBond Market & Verified Momentum Stock Ideas - baoquankhu1.vn
Biopharma Reaches 50% Enrollment in New ALS Drug Program - streetwisereports.com
MediciNova, Inc. (NASDAQ:MNOV) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
D. Boral Capital Reaffirms “Buy” Rating for MediciNova (NASDAQ:MNOV) - Defense World
Medicinova Inc Stock (MNOV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):